This website is intended for U.S. Healthcare Professionals.
REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
The recommended starting dose for relapsed
or refractory MCL is 25 mg/day orally on
Days 1-21 of repeated 28-day cycles.
Dosing Cycle with REVLIMID 25 mg
Treatment should be continued until disease progression or unacceptable toxicity
Important Dosing Information
The capsules should not be opened, broken, or chewed
REVLIMID is primarily excreted unchanged by the kidney. Since elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Monitor renal function
Monitor CBCs weekly for the first cycle (28 days), every 2 weeks during cycles 2-4, then monthly thereafter
Treatment is continued or modified based on clinical and laboratory findings
Dose modification guidelines are recommended to manage Grade 3/4 neutropenia or thrombocytopenia. For non-hematologic Grade 3/4 toxicities judged to be related to REVLIMID, hold treatment and restart at next lower dose level when toxicity has resolved to ≤Grade 2
For Grade 3 or 4 tumor flare reaction (TFR), recommended to withhold treatment with REVLIMID until TFR resolves to ≤Grade 1
Patients may require dose interruption and/or reduction
Patients may require the use of blood product support and/or growth factors